Tag: Novo Nordisk

Market News

Novo Obesity Strategy As Lilly Extends The GLP-1 Lead

Novo wants investors to look forward. Lilly keeps giving them reasons to look at the scoreboard. The pill race, Medicare,...

25/09/2026

18 views

Read More

Market News

Novo Nordisk Shares Drop Sharply After Heart Drug Trial Misses Mark

When Novo Nordisk announced its heart medicine didn't deliver the hoped-for results in a major trial, the market reacted instantly...

31/07/2026

12 views

Read More

Market News

Novo Nordisk and Eli Lilly Compete in Obesity Pill Market Ahead of Medicare Coverage

Have you ever wondered what happens when two pharmaceutical powerhouses go head-to-head in one of the biggest health markets of...

08/06/2026

7 views

Read More

Market News

High Dose Wegovy Delivers Stronger Weight Loss Results

New data on the higher dose of Wegovy reveals some patients losing almost 28% of their body weight. But who...

12/05/2026

5 views

Read More

Global Companies

Novo Nordisk Faces Ozempic Generics Challenge in Canada

The first generic versions of Ozempic have just been approved in Canada, marking a potential turning point for Novo Nordisk's...

11/05/2026

12 views

Read More

Market News

Novo Nordisk Q1 2026: Wegovy Pill Sales Surge Beats Forecasts- Deciding to use investment categories like Stocks and Market News due to financial content focus.

Novo Nordisk just posted impressive Q1 numbers with its Wegovy pill smashing sales forecasts in the US. The company raised...

11/05/2026

7 views

Read More

Market News

Novo Nordisk Wegovy Pill Shakes Up Eli Lilly Weight Loss Race

Just months after Novo Nordisk launched its Wegovy pill, the weight loss market is seeing unexpected shifts. Eli Lilly's response...

06/05/2026

6 views

Read More

Altcoins

Novo Nordisk Ireland Expansion Challenges Eli Lilly

Novo Nordisk just poured over $500 million into an Irish facility to ramp up production of their game-changing Wegovy pill....

02/03/2026

10 views

Read More

Market News

Novo Nordisk CagriSema: Next Steps After Trial Setback

Novo Nordisk's CagriSema showed 23% weight loss but fell short of Zepbound's results in a head-to-head trial, sending shares tumbling....

26/02/2026

7 views

Read More

Market News

Eli Lilly Widens Lead in Obesity Drug Race Over Novo Nordisk

Eli Lilly just landed another major blow to Novo Nordisk in the high-stakes obesity drug battle. With Zepbound showing superior...

24/02/2026

6 views

Read More